1-3 of 3
Andoni Echaniz-Laguna
Close
Sort by
Journal Articles

Hereditary transthyretin amyloidosis in the era of RNA interference, antisense oligonucleotide, and CRISPR-Cas9 treatments

Clinical Trials & Observations
David Adams, Vincent Algalarrondo, Andoni Echaniz-Laguna
Journal: Blood
Blood (2023) 142 (19): 1600–1612.
https://doi.org/10.1182/blood.2023019884
Published: 2023
Journal Articles

CANOMAD: a neurological monoclonal gammopathy of clinical significance that benefits from B-cell–targeted therapies

CME Clinical Trials & Observations
Marie Le Cann, Françoise Bouhour, Karine Viala, Laurence Simon, Céline Tard, Cédric Rossi, Guillaume Morel, Emmeline Lagrange, Laurent Magy, Alain Créange, Maud Michaud, Jérôme Franques, Andoni Echaniz-Laguna, Jean-Christophe Antoine, Marine Baron, Bertrand Arnulf, Angela Puma, Emilien Delmont, Thierry Maisonobe, Véronique Leblond, Damien Roos-Weil
Journal: Blood
Blood (2020) 136 (21): 2428–2436.
https://doi.org/10.1182/blood.2020007092
Published: 2020
Includes: Supplemental data
Journal Articles

Mitochondrial myopathy caused by arsenic trioxide therapy

Brief Report
Andoni Echaniz-Laguna, Aurélien Benoilid, Stéphane Vinzio, Luc-Matthieu Fornecker, Béatrice Lannes, Jean-Pierre Goullé, Frank Broly, Bénédicte Mousson de Camaret
Journal: Blood
Blood (2012) 119 (18): 4272–4274.
https://doi.org/10.1182/blood-2011-10-385138
Published: 2012
Includes: Supplemental data